---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004211"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T11:53:36.652692+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences simufilam reduces seizures 60% in TSC mouse model; H1 2026 clinical trials planned

## Summary
- Preclinical data: simufilam reduced seizure frequency by 60% vs. vehicle in focal onset seizure mouse model (p<0.0001).
- More mice achieved seizure freedom: 11/32 simufilam vs. 3/29 vehicle (p=0.0343).
- Human safety data from 1,929-patient Phase 3 Alzheimer's studies show favorable safety profile with no serious SAEs attributed to drug.
- Company plans to initiate first clinical study in TSC-related epilepsy in H1 2026.

## SEC filing metadata
- accession: 0001171843-25-004211
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184325004211/0001171843-25-004211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184325004211/f8k_062925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004211
- JSON: https://secwatch.observer/filing/0001171843-25-004211.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.